HIMS-Novo Wegovy Deal Triggers Bullish Analyst Revisions
Hims & Hers jumped about 49% after announcing a deal to offer Novo Nordisk’s Wegovy and Ozempic on its telehealth platform, a move that reduces legal risk as Novo dropped its lawsuit. Analysts at Citi, Deutsche Bank, Bank of America, and Needham issued more favorable views and higher price targets (up to about $30), signaling optimism that the partnership could unlock significant new revenue from official doses. TipRanks shows a Moderate Buy consensus with upside to current levels.